CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that preclinical data on three of its pipeline candidates will be highlighted at the XXIII International Complement Workshop (ICW) taking place August 1-5, 2010, in New York City. During the meeting, preclinical data on Taligen’s drug candidates, TT30, TT32 and TT33, will be presented, demonstrating the company’s progress in generating an emerging product pipeline in multiple therapeutic areas including paroxysmal nocturnal hemoglobinuria (PNH), age-related macular degeneration (AMD) and organ transplant.